JP2019532633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532633A5 JP2019532633A5 JP2019515405A JP2019515405A JP2019532633A5 JP 2019532633 A5 JP2019532633 A5 JP 2019532633A5 JP 2019515405 A JP2019515405 A JP 2019515405A JP 2019515405 A JP2019515405 A JP 2019515405A JP 2019532633 A5 JP2019532633 A5 JP 2019532633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022158138A JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189804.4 | 2016-09-20 | ||
| EP16189804 | 2016-09-20 | ||
| PCT/EP2017/073712 WO2018054940A1 (en) | 2016-09-20 | 2017-09-20 | Diagnostic anti-pd-l1 antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158138A Division JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532633A JP2019532633A (ja) | 2019-11-14 |
| JP2019532633A5 true JP2019532633A5 (enExample) | 2020-11-12 |
| JP7525261B2 JP7525261B2 (ja) | 2024-07-30 |
Family
ID=56979447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515405A Active JP7525261B2 (ja) | 2016-09-20 | 2017-09-20 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
| JP2022158138A Pending JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158138A Pending JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10738120B2 (enExample) |
| EP (1) | EP3515942B1 (enExample) |
| JP (2) | JP7525261B2 (enExample) |
| CN (1) | CN109963872B (enExample) |
| AU (1) | AU2017329780B2 (enExample) |
| CA (1) | CA3037230A1 (enExample) |
| ES (1) | ES3049875T3 (enExample) |
| IL (1) | IL265485B2 (enExample) |
| WO (1) | WO2018054940A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| BR112019006504A2 (pt) * | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| CN113795511B (zh) * | 2019-01-23 | 2024-07-23 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| CN116400075B (zh) * | 2022-10-14 | 2024-01-05 | 江西烈冰生物科技有限公司 | 检测狼疮性肾炎标志物的试剂及方法 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014165422A1 (en) * | 2013-04-02 | 2014-10-09 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| US9885721B2 (en) * | 2014-05-29 | 2018-02-06 | Spring Bioscience Corporation | PD-L1 antibodies and uses thereof |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| EP3254110B1 (en) * | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
-
2017
- 2017-09-20 AU AU2017329780A patent/AU2017329780B2/en active Active
- 2017-09-20 CA CA3037230A patent/CA3037230A1/en active Pending
- 2017-09-20 WO PCT/EP2017/073712 patent/WO2018054940A1/en not_active Ceased
- 2017-09-20 EP EP17778222.4A patent/EP3515942B1/en active Active
- 2017-09-20 CN CN201780071407.5A patent/CN109963872B/zh active Active
- 2017-09-20 ES ES17778222T patent/ES3049875T3/es active Active
- 2017-09-20 IL IL265485A patent/IL265485B2/en unknown
- 2017-09-20 US US16/334,699 patent/US10738120B2/en active Active
- 2017-09-20 JP JP2019515405A patent/JP7525261B2/ja active Active
-
2022
- 2022-09-30 JP JP2022158138A patent/JP2023011568A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12473354B2 (en) | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| US11525003B2 (en) | Anti-B7-H3 antibodies and diagnostic uses thereof | |
| JP7443298B2 (ja) | ヒト成長分化因子１５（ｇｄｆ－１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 | |
| JP6715770B2 (ja) | モノクローナル抗ｔｋ１抗体 | |
| JP2015533788A5 (enExample) | ||
| WO2015181342A1 (en) | Pd-l1 antibodies and uses thereof | |
| JP2023011568A (ja) | 診断用抗ｐｄ－ｌ１抗体およびその使用 | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EP4010706A1 (en) | Clinical management of oropharyngeal squamous cell carcinoma | |
| RU2016116773A (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
| EP3098602B1 (en) | Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning | |
| US20180136216A1 (en) | Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus | |
| EP3963332A1 (en) | Biomarkers for disease progression in squamous cell carcinoma | |
| US20240026034A1 (en) | Antibodies specific for qsox1 and methods of using the same | |
| WO2009123145A1 (ja) | パラスポリン－１受容体及びその用途 | |
| MX2023008142A (es) | Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y usos de los mismos. | |
| CA3193619A1 (en) | Method for detecting expression or clustering of cell surface moieties | |
| CN104391114A (zh) | Elisa方法定量测定人血清中重组人鼠嵌合抗cd20单克隆抗体浓度 | |
| EA044887B1 (ru) | Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа | |
| TH1801001202A (th) | แอนติบอดีและการสอบวิเคราะห์สำหรับการตรวจหา cd 37 |